Industry keeps up the pressure on UK early access scheme; new 'promising innovation medicine' designation in sight
This article was originally published in Scrip
The life sciences industry in the UK is continuing to put pressure on the government in an effort to make it deliver on the much-vaunted but still-to-materialize early access to medicines scheme. There is speculation that an announcement on the scheme is not far off, with a new “promising innovation medicine” designation expected to be introduced as part of it.
You may also be interested in...
The loss of fast-track status for setmelanotide at the European Medicines Agency means the review of the potential treatment of two rare genetic disorders of obesity will take longer than Rhythm Pharmaceuticals had originally hoped.
Swiss company Santhera's lengthy and problem-laden journey to repurpose its already marketed idebenone for use in Duchenne Muscular Dystrophy has ended in failure. The company has withdrawn its EU filing for the product following its announcement that it was halting development.
Novartis seems to have accepted the fact that the indication granted for Piqray in the EU means there is little scope for the advanced breast cancer drug to be used in markets such as the UK.